Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 468 500 KRW 2.52% Market Closed
Market Cap: 25.1T KRW

Alteogen Inc
Other Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Alteogen Inc
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Alteogen Inc
KOSDAQ:196170
Other Receivables
â‚©1.3B
CAGR 3-Years
4%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Other Receivables
â‚©51.8B
CAGR 3-Years
-3%
CAGR 5-Years
67%
CAGR 10-Years
2%
V
Voronoi Inc
KOSDAQ:310210
Other Receivables
â‚©167.9m
CAGR 3-Years
283%
CAGR 5-Years
67%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Other Receivables
â‚©14.4B
CAGR 3-Years
83%
CAGR 5-Years
56%
CAGR 10-Years
49%
A
ABL Bio Inc
KOSDAQ:298380
Other Receivables
â‚©335.4m
CAGR 3-Years
-15%
CAGR 5-Years
13%
CAGR 10-Years
N/A
D
DND PharmaTech Inc
KOSDAQ:347850
Other Receivables
â‚©2.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Alteogen Inc
Glance View

Market Cap
25T KRW
Industry
Biotechnology

In the bustling hub of South Korea's biotech industry, Alteogen Inc. has carved out a distinctive niche with its innovative approach to drug development. Founded in 2008, this company has harnessed the power of advanced biotechnology to specialize in the development of biopharmaceuticals, particularly focusing on creating long-acting protein therapeutics and biobetters. Alteogen's flagship technology, ALT-P7, a proprietary platform for producing antibody-drug conjugates, exemplifies how the company blends scientific ingenuity with commercial acumen. By reimagining existing biological drugs known as biobetters, Alteogen leverages its proprietary technologies to improve the efficacy and delivery of these treatments, promising enhanced convenience and therapeutic outcomes for patients. Financially, Alteogen thrives through both strategic partnerships and its own product pipeline. The company secures revenue by licensing its technology platforms to global pharmaceutical giants, thereby earning milestone payments and royalties. Additionally, Alteogen's ongoing research and development efforts continuously expand its portfolio, particularly in biosimilars—biological products highly similar to already-approved reference products. This dual-pronged approach, combining its proprietary biotechnological innovations with robust strategic alliances, positions Alteogen not just as a player but as an innovator in the biopharmaceutical sector, with the potential for significant impact in the realm of chronic disease treatment.

Intrinsic Value
231 338.58 KRW
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Alteogen Inc's Other Receivables?
Other Receivables
1.3B KRW

Based on the financial report for Jun 30, 2025, Alteogen Inc's Other Receivables amounts to 1.3B KRW.

What is Alteogen Inc's Other Receivables growth rate?
Other Receivables CAGR 5Y
14%

Over the last year, the Other Receivables growth was 6%. The average annual Other Receivables growth rates for Alteogen Inc have been 4% over the past three years , 14% over the past five years .

Back to Top